Analyzing Century Therapeutics (NASDAQ:IPSC) & Emisphere Technologies (OTCMKTS:EMIS)

Century Therapeutics (NASDAQ:IPSC) and Emisphere Technologies (OTCMKTS:EMIS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Profitability

This table compares Century Therapeutics and Emisphere Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	-19.10%	-11.53%	-6.94%
Emisphere Technologies	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Century Therapeutics and Emisphere Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1	0	4	0	2.60
Emisphere Technologies	0	0	0	0	0.00

Century Therapeutics currently has a consensus price target of $3.75, suggesting a potential upside of 542.67%. Given Century Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Century Therapeutics is more favorable than Emisphere Technologies.

Institutional and Insider Ownership

50.2% of Century Therapeutics shares are owned by institutional investors. 5.0% of Century Therapeutics shares are owned by insiders. Comparatively, 72.9% of Emisphere Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Century Therapeutics and Emisphere Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$114.13 million	0.44	-$126.57 million	($0.29)	-2.01
Emisphere Technologies	N/A	N/A	N/A	N/A	N/A

Emisphere Technologies has lower revenue, but higher earnings than Century Therapeutics.

Summary

Century Therapeutics beats Emisphere Technologies on 5 of the 9 factors compared between the two stocks.

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

About Emisphere Technologies

Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.